



Substitute for form 1449A/B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	09/937,181-Conf. #6148	
			Filing Date	January 10, 2002	
			First Named Inventor	Geoffrey P. Dobson	
			Art Unit	1651	
			Examiner Name	R. A. Davis	
Sheet	1	of	1	Attorney Docket Number	36749-200650

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ -Number ⁴ -Kind Code ⁵ (if known)				


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
LD	CA	Canyon, Sarah J. and Dobson, Geoffrey P., "Protection against ventricular arrhythmias and cardiac death using adenosine and lidocaine during regional ischemia in the in vivo rat," <i>Am J Physiol Heart Circ Physiol</i> 287:H1286-H1295 American Physiological Society (2004).			
LD	CB	Dobson, Geoffrey P., "Organ arrest, protection and preservation: natural hibernation to cardiac surgery," <i>Comparative Biochemistry and Physiology, Part B</i> 139:469-485, Elsevier Inc. (2004).			
LD	CC	Dobson, Geoffrey P., and Jones, Michael W., "Adenosine and lidocaine: A new concept in nondepolarizing surgical myocardial arrest, protection, and preservation," <i>The Journal of Thoracic and Cardiovascular Surgery</i> 127:794-805 (March 2004).			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	9/1/05
-----------------------	--	--------------------	--------



Docket No.: 36749-200650
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Geoffrey P. Dobson

Application No.: 09/937,181

Confirmation No.: 6148

Filed: January 10, 2002

Art Unit: 1651

For: ORGAN ARREST, PROTECTION AND
PRESERVATION

Examiner: R. A. Davis

Certification?

*Also new
drugs?*

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed after the mailing date of a Final Office Action or Notice of Allowance, whichever occurred first, but on or before payment of the Issue Fee (37 CFR 1.97(d)). Applicant hereby petitions that the Information Disclosure Statement be considered.

It is not believed that these references are prior art based on their publication dates. These references are being submitted to allow the Examiner to make note of the references.

A copy of each reference on the PTO/SB/08 is attached.

12/03/2004 CNGUYEN 00000109 09937181

01 FC:1806

180.00 DA


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 22-0261 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0261, under Order No. 36749-200650.

Dated: December 2, 2004

Respectfully submitted,

By 
Michael A. Gollin

Registration No.: 31,957
VENABLE LLP
P.O. Box 34385
Washington, DC 20043-9998
(202) 344-4000
(202) 344-8300 (Fax)
Attorney/Agent For Applicant

599796v1